Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin vs pioglitazone vs vitamin E for non-alcoholic fatty liver disease in type 2 diabetes
IRCT20190701044062N4Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Nov 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM) comparing Empagliflozin arm, Pioglitazone arm and Vitamin E arm (3 arms). Started Nov 2020; status: completed.
02
Drugs
empagliflozinpioglitazonevitamin e
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on IRCT20190701044062N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190701044062N4.